{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["63(1)"],"submitter":["Yu Y"],"pubmed_abstract":["<h4>Context</h4>Xiao-Luo-Wan (XLW), a classical prescription in traditional Chinese medicine, has therapeutic effects on uterine fibroids (UFs). Herein, its anti-UF effects were examined using a systematic pharmacological method.<h4>Objective</h4>To explore the active ingredients of XLW <i>via</i> mass spectrometry and its potential effects on UFs by network pharmacology, molecular docking, and experimental validation.<h4>Materials and methods</h4>A mass spectrometer was used to scrutinize the composition of the XLW drug-containing serum. The critical targets and potential mechanisms of XLW against UFs were predicted by network pharmacology and molecular docking. Next, human uterine leiomyoma cells (UMCs) were treated with 20%, 30%, or 40% XLW serum for 24 h, 48 h or 72 h. Cell viability w"],"journal":["Pharmaceutical biology"],"pagination":["201-217"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11999358"],"repository":["biostudies-literature"],"pubmed_title":["Integrated pharmacoanalysis, bioinformatics analysis, and experimental validation to identify the ingredients and mechanisms of Xiao-Luo-Wan in uterine fibroids treatment."],"pmcid":["PMC11999358"],"pubmed_authors":["Liu H","Zhang H","Yang F","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Integrated pharmacoanalysis, bioinformatics analysis, and experimental validation to identify the ingredients and mechanisms of Xiao-Luo-Wan in uterine fibroids treatment.","description":"<h4>Context</h4>Xiao-Luo-Wan (XLW), a classical prescription in traditional Chinese medicine, has therapeutic effects on uterine fibroids (UFs). Herein, its anti-UF effects were examined using a systematic pharmacological method.<h4>Objective</h4>To explore the active ingredients of XLW <i>via</i> mass spectrometry and its potential effects on UFs by network pharmacology, molecular docking, and experimental validation.<h4>Materials and methods</h4>A mass spectrometer was used to scrutinize the composition of the XLW drug-containing serum. The critical targets and potential mechanisms of XLW against UFs were predicted by network pharmacology and molecular docking. Next, human uterine leiomyoma cells (UMCs) were treated with 20%, 30%, or 40% XLW serum for 24 h, 48 h or 72 h. Cell viability w","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-01T17:50:22.51Z","creation":"2025-06-26T03:06:51.257Z"},"accession":"S-EPMC11999358","cross_references":{"pubmed":["40219728"],"doi":["10.1080/13880209.2025.2485905"]}}